Home › Funds › Samsara BioCapital, LLC › AQST
Samsara BioCapital, LLC position in AQST
AQUESTIVE THERAPEUTICS INC · Health Care
Samsara BioCapital, LLC reported holding 2,434,367 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.3M, representing 1.07% of its reported portfolio and ranking #14 among its reported holdings. Samsara BioCapital, LLC has disclosed AQST holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's AQST position evolved
Samsara BioCapital, LLC first disclosed a stake in AQST in Q3 2025 at 2,500,000 shares (US$14.0M). The position peaked in Q4 2025 at 2,500,000 shares, worth US$16.1M. Across 5 filings, Samsara BioCapital, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 2,434,367 shares valued at US$11.3M — a reduction of -65,633 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.50M | $13.97M | New |
| Q4 2025 | 2.50M | $16.15M | Hold |
| Q1 2026 | 2.50M | $10.38M | Hold |
| Q2 2026 | 2.50M | $10.40M | Hold |
| Q3 2026 | 2.43M | $11.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Rosalind Advisors, Inc. (US$9.3M), Propel Bio Management, LLC (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $45.42M · Q3 2026
- Rosalind Advisors, Inc. 2.00M sh · $9.26M · Q3 2026
- Propel Bio Management, LLC 278.72K sh · $8.61M · Q3 2026
- Blue Owl Capital Holdings LP 1.39M sh · $6.44M · Q3 2026
- Sio Capital Management, LLC 1.28M sh · $5.92M · Q3 2026
- DAFNA Capital Management LLC 640.91K sh · $2.97M · Q3 2026
- Everstar Asset Management, LLC 614.11K sh · $2.84M · Q3 2026
- Bracebridge Capital, LLC 459.22K sh · $2.13M · Q3 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held AQST?
Samsara BioCapital, LLC has disclosed AQST holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Samsara BioCapital, LLC's current position in AQST?
As of Q3 2026, Samsara BioCapital, LLC holds 2.43M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $11.27M, representing 1.07% of its reported portfolio and ranking #14.
Has Samsara BioCapital, LLC been buying or selling AQST?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC reduced its position in AQST. The position peaked in Q4 2025 at 2.50M shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Rosalind Advisors, Inc., Propel Bio Management, LLC, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.